These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 23117502)

  • 21. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.
    Hunt PW; Cao HL; Muzoora C; Ssewanyana I; Bennett J; Emenyonu N; Kembabazi A; Neilands TB; Bangsberg DR; Deeks SG; Martin JN
    AIDS; 2011 Nov; 25(17):2123-31. PubMed ID: 21881481
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
    Bedell R; Heath KV; Hogg RS; Wood E; Press N; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 2003 Oct; 8(5):379-84. PubMed ID: 14640384
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study.
    Zhang F; Dou Z; Ma Y; Zhang Y; Zhao Y; Zhao D; Zhou S; Bulterys M; Zhu H; Chen RY
    Lancet Infect Dis; 2011 Jul; 11(7):516-24. PubMed ID: 21600849
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intestinal parasitosis in relation to CD4+T cells levels and anemia among HAART initiated and HAART naive pediatric HIV patients in a Model ART center in Addis Ababa, Ethiopia.
    Mengist HM; Taye B; Tsegaye A
    PLoS One; 2015; 10(2):e0117715. PubMed ID: 25658626
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prognostic value of baseline CD4(+) cell count beyond 6 months of antiretroviral therapy in HIV-positive patients in a resource-limited setting.
    Mills EJ; Bakanda C; Birungi J; Yaya S; Ford N;
    AIDS; 2012 Jul; 26(11):1425-9. PubMed ID: 22526520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania.
    Johannessen A; Naman E; Ngowi BJ; Sandvik L; Matee MI; Aglen HE; Gundersen SG; Bruun JN
    BMC Infect Dis; 2008 Apr; 8():52. PubMed ID: 18430196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of HIV-infected adolescents on antiretroviral therapy in Uganda: findings from a nationally representative cohort in Uganda.
    Bakanda C; Birungi J; Mwesigwa R; Nachega JB; Chan K; Palmer A; Ford N; Mills EJ
    PLoS One; 2011 Apr; 6(4):e19261. PubMed ID: 21559441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early mortality after late initiation of antiretroviral therapy in the TREAT Asia HIV Observational Database (TAHOD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) Asia-Pacific.
    Rupasinghe D; Kiertiburanakul S; Kamarulzaman A; Zhang F; Kumarasamy N; Chaiwarith R; Merati TP; Do CD; Khusuwan S; Avihingsanon A; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Chan YJ; Pujari S; Ng OT; Choi JY; Sim B; Tanuma J; Sangle S; Ross J; Law M
    HIV Med; 2020 Jul; 21(6):397-402. PubMed ID: 31852025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Higher Risks of Virologic Failure and All-Cause Deaths Among Older People Living with HIV in Chongqing, China.
    Wu G; Zhou C; Zhang X; Zhang W; Lu R; Ouyang L; Xing H; Shao Y; Ruan Y; Qian HZ
    AIDS Res Hum Retroviruses; 2019; 35(11-12):1095-1102. PubMed ID: 31544479
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
    Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
    AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006-2015.
    Mangal TD; Meireles MV; Pascom ARP; de Almeida Coelho R; Benzaken AS; Hallett TB
    BMC Infect Dis; 2019 Feb; 19(1):206. PubMed ID: 30819120
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnitude of opportunistic diseases and their predictors among adult people living with HIV enrolled in care: national level cross sectional study, Ethiopia.
    Weldegebreal T; Ahmed I; Muhiye A; Belete S; Bekele A; Kaba M
    BMC Public Health; 2018 Jul; 18(1):820. PubMed ID: 29970047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Baseline Xpert MTB/RIF ct values predict sputum conversion during the intensive phase of anti-TB treatment in HIV infected patients in Kampala, Uganda: a retrospective study.
    Namugenyi J; Musaazi J; Katamba A; Kalyango J; Sendaula E; Kambugu A; Fehr J; Castelnouvo B; Manabe YC; Ssengooba W; Sekaggya-Wiltshire C
    BMC Infect Dis; 2021 Jun; 21(1):513. PubMed ID: 34074248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.
    Ford D; Robins JM; Petersen ML; Gibb DM; Gilks CF; Mugyenyi P; Grosskurth H; Hakim J; Katabira E; Babiker AG; Walker AS;
    Am J Epidemiol; 2015 Oct; 182(7):633-43. PubMed ID: 26316598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and factors associated with the Minimum Dietary Diversity among HIV-positive women receiving Antiretroviral Therapy in Kabale district, Uganda.
    Kihembo P; Lubogo D
    J Hum Nutr Diet; 2024 Jun; 37(3):695-705. PubMed ID: 38446644
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
    Mocroft A; Staszewski S; Weber R; Gatell J; Rockstroh J; Gasiorowski J; Panos G; Monforte Ad; Rakhmanova A; Phillips AN; Lundgren JD;
    Antivir Ther; 2007; 12(3):325-33. PubMed ID: 17591022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of antiretroviral treatment on mortality trends of HIV-positive adults in rural Uganda: a longitudinal population-based study, 1999-2009.
    Kasamba I; Baisley K; Mayanja BN; Maher D; Grosskurth H
    Trop Med Int Health; 2012 Aug; 17(8):e66-73. PubMed ID: 22943381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and predictors of tuberculosis among HIV-infected adults after initiation of antiretroviral therapy in Nigeria, 2004-2012.
    Pathmanathan I; Dokubo EK; Shiraishi RW; Agolory SG; Auld AF; Onotu D; Odafe S; Dalhatu I; Abiri O; Debem HC; Bashorun A; Ellerbrock T
    PLoS One; 2017; 12(3):e0173309. PubMed ID: 28282390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of early initiation of first-line combination antiretroviral therapy in Uganda.
    Sempa J; Ssennono M; Kuznik A; Lamorde M; Sowinski S; Semeere A; Hermans S; Castelnuovo B; Manabe YC
    BMC Public Health; 2012 Sep; 12():736. PubMed ID: 22943068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with clinical progression in HIV-2 infected-patients: the French ANRS cohort.
    Matheron S; Pueyo S; Damond F; Simon F; Leprêtre A; Campa P; Salamon R; Chêne G; Brun-Vezinet F;
    AIDS; 2003 Dec; 17(18):2593-601. PubMed ID: 14685053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.